Meet our team during the 26th annual meeting of the European Society of Gene & Cell Therapy (ESGCT) in Lausanne (Switzerland), October 16th-19th, 2018. We will be located at booth #28.
Our solutions for both protein and virus production
FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).
FectoCHO™ Expression system is a 3 component kit optimized to work together that contains FectoCHO™ CD Medium, FectoPRO® Transfection Reagent and FectoPRO® Expression Booster. FectoCHO™ Expression System has been developed to reach the highest protein production ever seen in CHO cell lines.
PEIpro® is a DNA transfection reagent for production of viruses, recombinant proteins and antibodies either in adherent cells in presence of serum or in suspension HEK-293 cells grown in low serum or serum-free media.
PEIpro®-HQ is a highly qualified grade of PEIpro® reagent, especially developed for the production of clinical batches of recombinant proteins, antibodies or viral vectors. The PEIpro®-HQ grade is supplied with appropriate Quality Controls and documentation allowing its use as a qualified raw material in GMP processes for the manufacturing of clinical batches of therapeutic products.
Our solution for In vivo experiments
in vivo-jetPEI® is a transfection reagent especially designed for efficient delivery of any nucleic acids into animals.
- Poster 338: Addressing Large-Scale Viral Vector Manufacturing Using an Optimized Pei-Based Transfection Process
Abstract: With the progress in developing new viral vector systems guided by safety, specificity and potency considerations, several gene and cell based therapies are now more than ever closer to being clinically approved and commercially available to treat genetic diseases. Viral vector delivery systems, of which mainly adeno-associated viruses (AAV) and lentiviruses are produced by transient transfection of mammalian producer HEK-293 cell lines. Virus vector production using the right transient transfection method is crucial to provide the flexibility and reproducibility that is needed to scale-up from initial process development to manufacturing of high-quality grade viral vectors.
Here, we describe an optimized PEI-based virus production process for high-yielding viral vector production, compatible with different cell culture adherent and suspension systems. We further demonstrate the robust viral vector production yields, as well as the adaptability and reliability of the PEI-based transient gene expression approach to efficiently manufacture GMP-grade viral vectors at a sufficiently large scale for more advanced clinical trials, and in fine to drive commercialization of therapeutic vectors.
- Poster 338: Alternatives to viral vectors for nucleic acid-mediated therapies
Abstract: Nucleic acids have considerable potential as therapeutic agents in the treatment of pathologies including genetic diseases, viral infections, and cancer therapies. The major challenge for the use of nucleic acids in therapy lies in safely delivering these anionic macromolecules to their intended sites of action.
At Polyplus-transfection, we develop powerful non-viral vectors to safely deliver nucleic acids in vivo to target a wide range of tissues, through various routes of administrations. Of these reagents, in vivo-jetPEI® is widely acknowledged to deliver nucleic acids in animals; and coherently is selected as the delivery vector of choice in several drug development programs, notably for immunotherapies. To fulfill all the quality requirements associated to its use in Human, Polyplus-transfection® supplies preclinical grade and cGMP grade in vivo-jetPEI® reagents for a growing number of plasmid and oligonucleotide based-preclinical studies and clinical trials.
The convention will take place at the SwissTech Convention Center:
Route Louis-Favre 2, 1024 Ecublens.
Meet Valérie Kedinger and Pascale Belguise to discuss how to improve your process of Bioproduction and in vivo experiments. We will be happy to answer all your questions regarding transfection and to present relevant products adapted to protein or virus production.
Valerie Kedinger, PhD
in vivo & GMP
Pascale Belguise, PhD
Business Development Manager